Dr. John Oertle of Envita Medical Centers Highlights the Potential of Healthcare Data on Beyond the Medical Algorithm
Discovering more options for treating life threatening diseases, like cancer, may be possible with access to detailed healthcare data. “Let the data decide,” said Dr. John Oertle, Chief Medical Director, Envita Medical Centers, while explaining how their unique approach of personalized precision integrative oncology, based on detailed healthcare data, has been a gamechanger.
With their unique approach, many patients with late-stage cancers were able to progress towards a holistic recovery, despite being written off by standard cancer specialty facilities across the country. “The more you test, the more you see that each individual cancer patient is unique and different because of what caused it,” said Dr. Oertle. He added how various factors like genomics, immune system, carcinogenic toxins, gut health, and infection, contribute to triggering the disease.
Dr. Oertle and his team at Envita Medical Centers specialize in identifying these unique sets of root causative factors in each individual patient, to custom-develop treatment plans for their patients. These plans are based on detailed healthcare data, which play a crucial role in unlocking a multitude of options for patients.
To explain how healthcare data can revolutionize care, going beyond the standard options available through insurance-based care, Dr. Oertle cited an example of breast cancer treatment, since October is dedicated to Breast Cancer Awareness. He said that typically breast cancer treatment protocols are dictated by factors like its stage, hormone sensitivity, and the presence of certain growth factors like HER2, but at Envita they test for many other biomarkers to custom design a comprehensive treatment protocol for each patient.
Inspired by the success of their patients in the past 25 years, Envita Medical Centers is now making their innovative treatment and preventive care options accessible to a greater number of people through employer-based self-funded health plans. “Our treatment was half the cost of the standard of care protocols nationwide,” added Dr. Oertle, highlighting the result of a 3rd party actuarially certified study on Envita's treatment program.*
To know more about Envita's revolutionary treatment program, insurance coverage, and how Dr. Oertle himself experienced the benefits of Envita's approach, tune into this podcast.
* Data is based on our analysis of records for 87 out of 129 patients that participated in Envita's treatment program in 2020. 42 patients were removed from the cohort due the patient's inability to start or complete Envita's prescribed treatment for a variety of reasons, including but not limited to, advanced disease state, disease progression, or inability to travel.
